Supplemental Table 3. Summary of Combined Effects of Individual Cervicovaginal Infections

Supplemental Table 3. Summary of combined effects of individual cervicovaginal infections (CVI) and hormonal contraception (HC) on markers of cervical immunity after adjusted for other individual CVIs, symptoms and signs (multivariable analysis via generalized linear models). The highlighted boxes show statistically significant differences (p<.05) between COC and no-HC and DMPA and no-HC when compared within the same CVI group. P values, ↑ and ↓ indicate significant increases or decreases, respectively, in levels of these mediators.

C V I - f r Gonorrhea Chlamydia HSV-2 TV Candida Nugent Nugent e 4-6 7-10 e N=47 N=34 N=473 N=43 N=101 N=161 N=265

N = 1 0 6 Mediators C DMPA COC DMPA COC DMPA COC DMP COC DMPA COC DMPA COC DMPA COC DMPA O N=46 N=13 N=23 N=14 N=13 N=168 A N=12 N=14 N=40 N=36 N=53 N=62 N=97 N=100 C N=1 N 72 = 4 5 ↑ . IL-1β .15 .22 .58 .36 .13 .12 .08 ↓.01 ↓.00 .76 .76 .43 .23 ↑.00 .82 0 0 ↑ . IL-6 .42 .53 .52 .93 .81 ↑.01 .45 .59 .93 .57 .87 .86 .67 ↑.00 .43 0 1 ↑ . IL-8 .73 .97 .17 .33 .22 ↑.00 .94 ↓.04 .11 .21 .44 .91 .78 ↑.00 .22 0 2 . MIP-3α 1 .84 .79 .07 .21 .12 ↑.00 .07 .29 ↓.00 ↑.00 .35 .82 .45 ↑.00 .78 9 . VEGF 2 .60 .78 .38 .32 .40 ↑.04 .22 .42 .40 .70 .68 .20 .30 ↑0.00 .62 2 . ↑.0 RANTES 9 ↑.03 .84 .10 .90 .11 .17 .79 .11 .22 ↑.04 .35 ↑.05 .21 ↑.00 0 3 . ICAM-1 6 .37 .95 .55 .78 .29 .53 .70 .85 .93 .52 .11 .92 .61 0.94 .44 4 ↑ . ↓.0 IL-1RA .46 058 ↓.01 .14 ↓.05 .71 .75 .19 .41 .33 .18 .25 .37 .07 0 0 5 . SLPI 3 .44 .70 ↓.05 .98 .97 ↑.00 .34 .62 .21 ↑.00 .56 .13 .62 ↑.00 .88 6 . ↓.0 BD2 0 ↓.02 .23 .21 .11 ↓.01 ↓.00 .06 ↓.00 ↓.04 .49 .12 .24 .65 .78 0 7 . IL-1RA/IL1 0 .38 ↓.01 .07 .99 .64 ↓.04 .80 ↓0.00 ↓.00 .27 .18 .80 .53 ↓.00 .25 8